Logging myself monthly for dut 0.5 mg and min5mg oral
    Research/Science 12/24/2024

    From the encyclopedia
    Dutasteride →

    Heavy duty finasteride that comes with higher risks

    Minoxidil →

    An essential vasodilator with some anti-androgenic effects

    RU58841 →

    a potent but unapproved and potentially problematic topical anti-androgen

    At a glance
    In this treatment experience post, the primary subjects mentioned are
    💊 Dutasteride (oral) 0.5 mg 10 days
    💊 Minoxidil (oral) 5 mg 10 days
    the tone is 😐 neutral with new hair growth results.

    Other terms

    The user is documenting their experience with oral dutasteride (dut) 0.5 mg and minoxidil (min) 5 mg for hair loss, planning to add RU58841 after three months. They previously used finasteride with success and are now experiencing increased shedding but also new hair growth.
    View this post in the Community →

    Similar Community Posts Join

    6 / 6 results

    Related Research

    6 / 6 results

      research Hair growth and rejuvenation: An overview

      81 citations , June 2010 in “Journal of Dermatological Treatment”
      This review discusses recent advancements in hair rejuvenation strategies and assesses the potential of herbal drugs as safer alternatives, but reports no new clinical results.

      research Therapeutic strategies for treating hair loss

      42 citations , March 2006 in “Drug Discovery Today: Therapeutic Strategies”
      This article discusses the need for rational strategies in developing hair loss drugs targeting specific events in hair follicle cycling, reporting no clinical findings but emphasizing the importance of understanding molecular controls.

      research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique

      March 2025 in “HAL (Le Centre pour la Communication Scientifique Directe)”
      This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.

      research Androgenetic Alopecia: An Update on Pathogenesis and Pharmacological Treatment

      August 2025 in “Drug Design Development and Therapy”
      This review article examines current drugs for androgenetic alopecia, focusing on their mechanisms and clinical efficacy, noting that while finasteride and minoxidil are commonly approved treatments, new drugs targeting different pathogenic pathways have emerged, offering a broader understanding and reference for AGA treatment options.